Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
GRFS

Grifols

$19.20

-0.48 (-2.44%)

05:30
03/07/19
03/07
05:30
03/07/19
05:30
Hot Stocks
Grifols to acquire 26% stake in Shanghai RAAS through strategic alliance »

Grifols and Shanghai RAAS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRFS

Grifols

$19.20

0.48 (2.56%)

05:39
02/08/19
02/08
05:39
02/08/19
05:39
Downgrade
Grifols rating change at Berenberg »

Grifols downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRFS

Grifols

$18.75

0.03 (0.16%)

12:34
02/07/19
02/07
12:34
02/07/19
12:34
Hot Stocks
Grifols gets FDA approval for Procleix Babesia assay »

Grifols announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$2.04

0.025 (1.24%)

, GRFS

Grifols

$19.33

0.26 (1.36%)

11:15
01/23/19
01/23
11:15
01/23/19
11:15
Recommendations
Rigel Pharmaceuticals, Grifols analyst commentary at H.C. Wainwright »

H.C. Wainwright boosts…

RIGL

Rigel Pharmaceuticals

$2.04

0.025 (1.24%)

GRFS

Grifols

$19.33

0.26 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$2.02

-0.065 (-3.13%)

, GRFS

Grifols

$19.07

-0.28 (-1.45%)

09:24
01/23/19
01/23
09:24
01/23/19
09:24
Recommendations
Rigel Pharmaceuticals, Grifols analyst commentary at Piper Jaffray »

Piper says Grifols deal…

RIGL

Rigel Pharmaceuticals

$2.02

-0.065 (-3.13%)

GRFS

Grifols

$19.07

-0.28 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$2.02

-0.065 (-3.13%)

, GRFS

Grifols

$19.07

-0.28 (-1.45%)

07:37
01/23/19
01/23
07:37
01/23/19
07:37
Hot Stocks
Grifols to commercialize Rigel Pharmaceuticals' fostamatinib in Europe »

Rigel Pharmaceuticals…

RIGL

Rigel Pharmaceuticals

$2.02

-0.065 (-3.13%)

GRFS

Grifols

$19.07

-0.28 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
GRFS

Grifols

$18.93

-0.05 (-0.26%)

07:39
01/08/19
01/08
07:39
01/08/19
07:39
Hot Stocks
Grifols receives FDA approval of Erytra Eflexis »

Grifols has received U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRFS

Grifols

$20.40

-0.29 (-1.40%)

07:03
11/23/18
11/23
07:03
11/23/18
07:03
Hot Stocks
Grifols in talks for $5B stake in China's Shanghai RAAS Blood Products »

Grifols S.A. disclosed on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRFS

Grifols

$20.34

0.91 (4.68%)

05:53
10/30/18
10/30
05:53
10/30/18
05:53
Upgrade
Grifols rating change at Santander »

Grifols upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRFS

Grifols

$20.06

0.36 (1.83%)

09:52
10/12/18
10/12
09:52
10/12/18
09:52
Hot Stocks
Grifols' ID CORE XT molecular diagnostic test approved by FDA »

Grifols received approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.